Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1beta) immune signaling pathways (TNF/IL-1 pathways)

The TNF-α and IL-1β-related immune pathways are critical signaling networks that orchestrate the body's inflammatory response to injury and infection (Source: PubMed, PMID: 28123206). Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 beta (IL-1β) are key pro-inflammatory cytokines that often act synergistically to induce the production of other cytokines, chemokines, and adhesion molecules (Source: NIH, StatPearls). These pathways primarily signal through the activation of the NF-κB and mitogen-activated protein kinase (MAPK) cascades, leading to the transcription of genes involved in cell proliferation, differentiation, and apoptosis (Source: UniProt, P01375, P01584). In many chronic inflammatory conditions, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, these pathways are pathologically overactive, leading to tissue destruction and systemic inflammation (Source: PubMed, PMID: 30241757). Therapeutic strategies targeting these pathways include monoclonal antibodies like adalimumab and canakinumab, which neutralize the cytokines, or receptor antagonists like anakinra, which prevent signal transduction (Source: PubChem). Dual inhibition of both TNF-α and IL-1β has been explored to achieve greater efficacy in refractory cases, although it requires careful monitoring for increased immunosuppressive risks (Source: ClinicalTrials.gov, NCT02087020). These pathways also play a role in the pathogenesis of metabolic syndromes and neurodegenerative diseases, highlighting their broad biological impact (Source: PubMed, PMID: 26439560). Monitoring efficacy often involves measuring systemic inflammatory markers like C-reactive protein or specific cytokine levels in the serum (Source: Mayo Clinic).

Other names

TNF-alpha/IL-1beta axisPro-inflammatory cytokine signalingTNF/IL-1 signalingTNF-alpha and IL-1-beta related pathways

Neutralization of TNF-alpha and IL-1beta cytokines or competitive inhibition of their respective receptors to prevent downstream pro-inflammatory signaling.